C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
3.675
+0.635 (20.89%)
Mar 9, 2026, 3:00 PM EDT - Market open
C4 Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Mar '26 Mar 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 359 | 185 | 254 | 278 | 289 | 1,566 | |
| Market Cap Growth | 69.90% | -27.16% | -8.73% | -3.60% | -81.55% | 9.83% | |
| Enterprise Value | 60 | 47 | 37 | 104 | 11 | 1,108 | |
| Last Close Price | 3.04 | 1.91 | 3.60 | 5.65 | 5.90 | 32.20 | |
| PS Ratio | 8.25 | 5.15 | 7.14 | 13.42 | 9.29 | 34.20 | |
| PB Ratio | 1.15 | 0.72 | 1.18 | 1.13 | 1.00 | 4.02 | |
| P/TBV Ratio | 1.16 | 0.72 | 1.18 | 1.13 | 1.00 | 4.02 | |
| EV/Sales Ratio | 1.66 | 1.30 | 1.03 | 5.02 | 0.35 | 24.20 | |
| Debt / Equity Ratio | 0.23 | 0.23 | 0.30 | 0.29 | 0.30 | 0.11 | |
| Net Debt / Equity Ratio | -0.92 | -0.92 | -0.93 | -0.86 | -0.86 | -1.05 | |
| Net Debt / EBITDA Ratio | 2.31 | 2.31 | 1.75 | 1.54 | 1.96 | 5.07 | |
| Net Debt / FCF Ratio | 2.39 | 2.39 | 3.08 | 1.94 | 2.24 | 4.63 | |
| Asset Turnover | 0.10 | 0.10 | 0.10 | 0.05 | 0.07 | 0.10 | |
| Quick Ratio | 7.60 | 7.60 | 5.49 | 6.21 | 6.23 | 6.15 | |
| Current Ratio | 7.81 | 7.81 | 5.71 | 6.34 | 6.46 | 6.36 | |
| Return on Equity (ROE) | -44.44% | -44.44% | -45.58% | -49.50% | -37.76% | -25.03% | |
| Return on Assets (ROA) | -18.43% | -18.43% | -20.17% | -21.53% | -17.27% | -11.32% | |
| Return on Capital Employed (ROCE) | -32.00% | -32.00% | -38.50% | -41.70% | -33.50% | -18.00% | |
| Earnings Yield | -35.39% | -56.72% | -41.44% | -47.58% | -44.38% | -5.36% | |
| FCF Yield | -33.48% | -53.64% | -25.71% | -38.98% | -38.58% | -5.64% | |
| Buyback Yield / Dilution | -19.49% | -19.49% | -39.75% | -1.59% | -6.13% | -304.93% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.